Wells Fargo & Company Cuts bluebird bio (NASDAQ:BLUE) Price Target to $3.00 : vimarsana.com

bluebird bio (NASDAQ:BLUE – Get Free Report) had its price target cut by Wells Fargo & Company from $4.00 to $3.00 in a report released on Wednesday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target would indicate a potential upside of 150.00% […]

Related Keywords

United States , America , Robertw Baird , William Blair , Us Bancorp , Morgan Stanley , Stifel Financial Corp , Nasdaq , Penserra Capital Management , Wells Fargo Company , Raymond James Associates , Get Free Report , Wells Fargo , Trading Down , Financial Corp , Capital Management , Aigen Investment Management , Bluebird Bio , Nasdaq Blue , Blue , Medical , Lower Price Target ,